Keyphrases
Independent Risk Factors
100%
Rituximab
100%
Pneumocystis Jirovecii
100%
Monoclonal Antibody
25%
Israel
12%
Inflammatory Diseases
12%
Patient Demographics
12%
Retrospective Survey
12%
Risk Factors
12%
Identify Risk
12%
Lymphopenia
12%
Immunocompromised Patients
12%
Cellular Immunity
12%
Hematological Malignancies
12%
Significant Risk Factors
12%
Pneumonia
12%
Steroid Treatment
12%
HIV Patients
12%
Enhanced Awareness
12%
Inflammatory Disorders
12%
Test-negative Design
12%
Bronchoalveolar Lavage
12%
Malignant Disorders
12%
Low Albumin
12%
Low BMI
12%
Immunomodulatory Drugs (IMiDs)
12%
High-dose Steroids
12%
Pneumonia Infection
12%
HIV-negative Patients
12%
Medicine and Dentistry
Case-Control Study
100%
Rituximab
100%
Pneumocystis Jirovecii
100%
Monoclonal Antibody
25%
Inflammatory Disorder
25%
Human Immunodeficiency Virus
25%
Body Mass Index
12%
Infection
12%
Awareness
12%
Drug Megadose
12%
Hematologic Malignancy
12%
Steroid Treatment
12%
Cellular Immunity
12%
Patient Population
12%
Patient with Pneumonia
12%
Lymphocytopenia
12%
Lung Lavage
12%
Immunomodulatory Drug
12%
Pharmacology, Toxicology and Pharmaceutical Science
Case-Control Study
100%
Rituximab
100%
Pneumocystis Jiroveci
100%
HIV
25%
Monoclonal Antibody
25%
Disease
12%
Inflammatory Disease
12%
Infection
12%
Steroid Treatment
12%
Hematologic Malignancy
12%
Lymphocytopenia
12%
Immunology and Microbiology
Rituximab
100%
Pneumocystis Jiroveci
100%
Monoclonal Antibody
25%
Inflammatory Disorder
25%
Human Immunodeficiency Virus
25%
Lymphocytopenia
12%
Adoptive Immunity
12%
Drug Megadose
12%
Awareness
12%
Immunomodulatory Drug
12%